Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib to prevent relapse after resection/ablation of HCV-related hepatocellular carcinoma
2010-020678-41Phase 2Active
- Sponsor
- Policlinico di Bari
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sorafenib in hepatocellular carcinoma (HCC) and chronic hepatitis C (CHC), sponsored by Policlinico di Bari. Primary endpoints: time to progression of disease, overall survival and 1 more. Started Sep 2010; status: active.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2010-020678-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020678-41.